Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

First Posted Date
2022-02-04
Last Posted Date
2023-02-08
Lead Sponsor
Beijing Tsinghua Chang Gung Hospital
Target Recruit Count
20
Registration Number
NCT05225116
Locations
🇨🇳

Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

First Posted Date
2022-02-03
Last Posted Date
2022-02-03
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
18
Registration Number
NCT05221775
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

First Posted Date
2022-02-02
Last Posted Date
2022-05-19
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
299
Registration Number
NCT05220020
Locations
🇨🇳

Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China

GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

Not Applicable
Recruiting
Conditions
Cholangiocarcinoma
Interventions
Drug: GEMOX Regimen
Drug: Lenvatinib
Drug: Toripalimab
First Posted Date
2022-01-31
Last Posted Date
2024-12-11
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
146
Registration Number
NCT05215665
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients

First Posted Date
2022-01-28
Last Posted Date
2023-06-13
Lead Sponsor
Zhejiang University
Target Recruit Count
39
Registration Number
NCT05213221
Locations
🇨🇳

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

First Posted Date
2022-01-18
Last Posted Date
2022-01-18
Lead Sponsor
Lion TCR Pte. Ltd.
Target Recruit Count
55
Registration Number
NCT05195294

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

First Posted Date
2022-01-12
Last Posted Date
2024-11-06
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
20
Registration Number
NCT05188118
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

First Posted Date
2022-01-11
Last Posted Date
2024-12-06
Lead Sponsor
University College, London
Target Recruit Count
60
Registration Number
NCT05185739
Locations
🇬🇧

Freeman Hospital, Newcastle Upon Tyne, United Kingdom

🇬🇧

Queen Elizabeth Hospital, Birmingham, United Kingdom

🇬🇧

Addenbrooke's Hospital, Cambridge, United Kingdom

and more 8 locations

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

First Posted Date
2021-12-28
Last Posted Date
2022-09-21
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
50
Registration Number
NCT05171335
Locations
🇺🇸

Houston Methodist Research Institute, Houston, Texas, United States

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

First Posted Date
2021-12-23
Last Posted Date
2024-04-04
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
122
Registration Number
NCT05168163
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Rapid City Regional Hospital, Rapid City, South Dakota, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 13 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy